AAPL   318.35 (+0.03%)
FB   227.22 (+0.78%)
GOOGL   1,428.35 (+0.71%)
AMZN   2,422.41 (+0.89%)
NVDA   344.84 (+1.58%)
CGC   17.86 (-17.77%)
MU   46.72 (+0.54%)
GE   6.65 (-2.06%)
TSLA   811.48 (+0.70%)
AMD   52.51 (+1.49%)
ACB   14.27 (-6.98%)
GILD   75.25 (-0.09%)
DIS   116.37 (-0.33%)
BA   146.48 (-2.23%)
AAPL   318.35 (+0.03%)
FB   227.22 (+0.78%)
GOOGL   1,428.35 (+0.71%)
AMZN   2,422.41 (+0.89%)
NVDA   344.84 (+1.58%)
CGC   17.86 (-17.77%)
MU   46.72 (+0.54%)
GE   6.65 (-2.06%)
TSLA   811.48 (+0.70%)
AMD   52.51 (+1.49%)
ACB   14.27 (-6.98%)
GILD   75.25 (-0.09%)
DIS   116.37 (-0.33%)
BA   146.48 (-2.23%)
AAPL   318.35 (+0.03%)
FB   227.22 (+0.78%)
GOOGL   1,428.35 (+0.71%)
AMZN   2,422.41 (+0.89%)
NVDA   344.84 (+1.58%)
CGC   17.86 (-17.77%)
MU   46.72 (+0.54%)
GE   6.65 (-2.06%)
TSLA   811.48 (+0.70%)
AMD   52.51 (+1.49%)
ACB   14.27 (-6.98%)
GILD   75.25 (-0.09%)
DIS   116.37 (-0.33%)
BA   146.48 (-2.23%)
AAPL   318.35 (+0.03%)
FB   227.22 (+0.78%)
GOOGL   1,428.35 (+0.71%)
AMZN   2,422.41 (+0.89%)
NVDA   344.84 (+1.58%)
CGC   17.86 (-17.77%)
MU   46.72 (+0.54%)
GE   6.65 (-2.06%)
TSLA   811.48 (+0.70%)
AMD   52.51 (+1.49%)
ACB   14.27 (-6.98%)
GILD   75.25 (-0.09%)
DIS   116.37 (-0.33%)
BA   146.48 (-2.23%)
Log in

NASDAQ:ALNYAlnylam Pharmaceuticals Stock Price, Forecast & News

$133.44
+0.34 (+0.26 %)
(As of 05/29/2020 09:46 AM ET)
Add
Compare
Today's Range
$133.31
Now: $133.44
$134.99
50-Day Range
$109.52
MA: $134.92
$145.63
52-Week Range
$65.95
Now: $133.44
$151.84
Volume12,678 shs
Average Volume804,373 shs
Market Capitalization$15.32 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.9
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. It provides ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. The company's development programs include Vutrisiran, an investigational RNAi therapeutic targeting transthyretin that is in Phase III trials for the treatment of transthyretin-mediated amyloidosis; Givosiran that is in Phase III trials to treat acute hepatic porphyrias; and Lumasiran, an investigational RNAi therapeutic, which is in Phase III clinical trials for glycolate oxidase to treat primary hyperoxaluria type 1. It is also developing Inclisiran, an investigational RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9 that is in Phase III clinical trials for the treatment of hypercholesterolemia; and Fitusiran, an investigational RNAi therapeutic that is in Phase III clinical trials for treating hemophilia A and B with or without inhibitors. In addition, the company engages in the development of Cemdisiran for complement-mediated diseases; ALN-AAT02 to treat alpha-1 anti-trypsin deficiency-associated liver disease; ALN-HBV02 for treating chronic hepatitis B virus infection; and other earlier-stage programs. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Read More
Alnylam Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.66 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ALNY
CUSIP02043Q10
Phone617-551-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$219.75 million
Book Value$11.76 per share

Profitability

Net Income$-886,120,000.00
Net Margins-310.01%

Miscellaneous

Employees1,323
Market Cap$15.32 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive ALNY News and Ratings via Email

Sign-up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter.

Alnylam Pharmaceuticals (NASDAQ:ALNY) Frequently Asked Questions

How has Alnylam Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Alnylam Pharmaceuticals' stock was trading at $101.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALNY stock has increased by 31.0% and is now trading at $133.44. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Alnylam Pharmaceuticals?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Alnylam Pharmaceuticals.

When is Alnylam Pharmaceuticals' next earnings date?

Alnylam Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Alnylam Pharmaceuticals.

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) issued its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($1.62) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.89) by $0.27. The biopharmaceutical company earned $71.94 million during the quarter, compared to analysts' expectations of $90.45 million. Alnylam Pharmaceuticals had a negative return on equity of 57.63% and a negative net margin of 310.01%. The company's revenue was up 173.6% on a year-over-year basis. During the same period in the prior year, the business earned ($1.42) EPS. View Alnylam Pharmaceuticals' earnings history.

What price target have analysts set for ALNY?

18 brokers have issued 12-month target prices for Alnylam Pharmaceuticals' stock. Their forecasts range from $74.00 to $202.00. On average, they anticipate Alnylam Pharmaceuticals' share price to reach $151.28 in the next year. This suggests a possible upside of 13.4% from the stock's current price. View analysts' price targets for Alnylam Pharmaceuticals.

Has Alnylam Pharmaceuticals been receiving favorable news coverage?

News stories about ALNY stock have trended extremely negative on Friday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Alnylam Pharmaceuticals earned a media sentiment score of -4.8 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutAlnylam Pharmaceuticals.

Who are some of Alnylam Pharmaceuticals' key competitors?

What other stocks do shareholders of Alnylam Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), NVIDIA (NVDA), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), Opko Health (OPK), AbbVie (ABBV) and Vertex Pharmaceuticals (VRTX).

Who are Alnylam Pharmaceuticals' key executives?

Alnylam Pharmaceuticals' management team includes the following people:
  • Dr. John M. Maraganore, CEO & Exec. Director (Age 56)
  • Mr. Barry E. Greene, Pres (Age 56)
  • Mr. Manmeet Singh Soni, Sr. VP, CFO & Principal Accounting Officer (Age 41)
  • Dr. Yvonne Greenstreet MBChB, MBA, Exec. VP & COO (Age 56)
  • Dr. Akshay K. Vaishnaw, Pres of R&D (Age 56)

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Who are Alnylam Pharmaceuticals' major shareholders?

Alnylam Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (10.70%), BlackRock Inc. (7.58%), Baillie Gifford & Co. (7.44%), State Street Corp (2.60%), Morgan Stanley (1.21%) and Morgan Stanley (1.21%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Marsha Fanucci, Philip A Sharp, Phillip A Sharp, Steven M Paul and Yvonne Greenstreet. View institutional ownership trends for Alnylam Pharmaceuticals.

Which institutional investors are selling Alnylam Pharmaceuticals stock?

ALNY stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Maverick Capital Ltd., Rockefeller Capital Management L.P., Morgan Stanley, Morgan Stanley, Federated Hermes Inc., Pictet Asset Management Ltd., and Quantitative Investment Management LLC. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Marsha Fanucci, Phillip A Sharp, Steven M Paul, and Yvonne Greenstreet. View insider buying and selling activity for Alnylam Pharmaceuticals.

Which institutional investors are buying Alnylam Pharmaceuticals stock?

ALNY stock was acquired by a variety of institutional investors in the last quarter, including The Manufacturers Life Insurance Company , BlackRock Inc., Janus Henderson Group PLC, Sumitomo Mitsui Trust Holdings Inc., Duquesne Family Office LLC, First Trust Advisors LP, Baillie Gifford & Co., and Capital World Investors. View insider buying and selling activity for Alnylam Pharmaceuticals.

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Alnylam Pharmaceuticals' stock price today?

One share of ALNY stock can currently be purchased for approximately $133.44.

How big of a company is Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals has a market capitalization of $15.32 billion and generates $219.75 million in revenue each year. The biopharmaceutical company earns $-886,120,000.00 in net income (profit) each year or ($8.11) on an earnings per share basis. Alnylam Pharmaceuticals employs 1,323 workers across the globe.

What is Alnylam Pharmaceuticals' official website?

The official website for Alnylam Pharmaceuticals is www.alnylam.com.

How can I contact Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-551-8200 or via email at [email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.